Oxcia - pre-IPO private placement of SEK 70m
Oxcia is a clinical stage drug development company with two DDR (DNA Damage and Repair) drug candidates targeting cancer and fibrosis. DDR is an emerging and prioritized scientific area with numerous big pharma companies investing in the field and several recent large M&A-deals. The proceeds will be used to finance finalization of two clinical phase I studies with read-out in 2021.
We thank Oxcia for the vote of confidence and congratulate on the successful transaction!
Latest news
Arctic Securities - Leadership Changes – Strengthening Arctic for the Future
We are pleased to announce leadership transitions at Arctic to support our long-term vision and continued success.
Arctic Securities - Arctic Securities er sertifisert rådgiver på Nasdaq First North Growth Market
Arctic Securities er godkjent som Certified Adviser (CA) på den alternative markedsplassen Nasdaq First North Growth Market i Sverige.
Arctic Securities - Arctic bøtelagt i Sverige – uenig i regelbrudd
Disiplinærnemnden ved Nasdaq Stockholm gir Arctic Securities en bot på 2 millioner SEK for ikke å ha informert børsen tidsnok om en endring i virksomheten.
Arctic Securities - Cavendish Hydrogen ASA - Prospectus
Cavendish Hydrogen has applied for admission to trading of its shares on the main board of the Oslo Stock Exchange. Arctic Securities AS is acting as joint lead manager. Please find the prospectus in connection with the Listing.
Arctic Securities - Arctic strengthens its position in the ECM market
Arctic has participated in six out of the ten largest ECM transactions this year. Arctic ranks second in both volume and number of transactions, according to Bloomberg.
Arctic Securities - Prospera High Yield 2024: Arctic number one in the Nordics
Arctic has been named the best analyst speaking partner and number one within Company Credit Research in the Nordics.